Skip to main content

Lipid Metabolism

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
normal dietary behaviorN/A1 trial
Active Trials
NCT01921075Completed9Est. Dec 2011
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
ObicetrapibPHASE_12 trials
Active Trials
NCT07794670Not Yet Recruiting400Est. May 2029
NCT05972278Active Not Recruiting22Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
NewAmsterdam PharmaObicetrapib
NewAmsterdam PharmaObicetrapib
Takedanormal dietary behavior

Clinical Trials (3)

Total enrollment: 431 patients across 3 trials

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Start: Sep 2026Est. completion: May 2029400 patients
Phase 2Not Yet Recruiting

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Start: Dec 2023Est. completion: Oct 202422 patients
Phase 1Active Not Recruiting
NCT01921075Takedanormal dietary behavior

Physiologic Plasticity of Intramyocardial Lipid Storage

Start: Jan 2010Est. completion: Dec 20119 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.